| Literature DB >> 35692398 |
Xinxin Wu1,2, Pengyi Yu1,2, Chuanliang Jia1,2, Ning Mao3, Kaili Che3, Guan Li3, Haicheng Zhang4, Yakui Mou1,2, Xicheng Song1,2.
Abstract
Objective: To investigate the application of computed tomography (CT)-based radiomics model for prediction of thyroid capsule invasion (TCI) in papillary thyroid carcinoma (PTC).Entities:
Keywords: computed tomography; machine learning; papillary thyroid carcinoma; radiomics; thyroid capsule invasion
Mesh:
Year: 2022 PMID: 35692398 PMCID: PMC9174423 DOI: 10.3389/fendo.2022.849065
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1The patient recruitment pathway in the two-center study.
Figure 2Workflow of data analysis. The workflow illustrates image segmentation and preprocessing, radiomics features extraction and selection, models construction and evaluation.
Clinicoradiological characteristics of the training, internal test, and external test cohorts.
| Training cohort (n=265) | Internal test cohort (n=114) | External test cohort (n=33) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| pTCI + (n=130) | pTC I− (n=135) |
| pTCI + (n=56) | pTCI − (n=58) |
| pTCI + (n=17) | pTCI − (n=16) |
| |
|
| 0.692 | 0.035 | 0.389 | ||||||
| Male | 30/23.1 | 35/25.9 | 38/67.9 | 50/86.2 | 4/23.5 | 7/43.8 | |||
| Female | 100/76.9 | 100/74.1 | 18/32.1 | 8/13.8 | 13/76.5 | 9/56.3 | |||
| Age (years) | 45.52 ± 11.88 | 43.87 ± 11.14 | 0.246 | 46.20 ± 11.01 | 44.60 ± 11.77 | 0.635 | 46.05 ± 13.41 | 44.88 ± 11.77 | 0.789 |
| TSH (mIU/L) | 2.60 ± 2.76 | 2.44 ± 1.18 | 0.551 | 2.41 ± 1.70 | 2.38 ± 1.17 | 0.915 | 2.28 ± 1.35 | 2.04 ± 0.92 | 0.927 |
| CT-MTD (cm) | 1.01 ± 0.58 | 0.99 ± 0.55 | 0.807 | 1.04 ± 0.48 | 0.95 ± 0.44 | 0.345 | 1.32 ± 0.50 | 1.08 ± 0.65 | 0.242 |
|
| <0.001 | 0.451 | <0.001 | ||||||
| Left | 66/50.8 | 60/44.4 | 27/48.2 | 23/39.7 | 5/29.4 | 3/18.75 | |||
| Right | 59/45.4 | 73/54.1 | 29/51.8 | 35/60.3 | 12/70.6 | 12/75.0 | |||
| Isthmus | 5/3.8 | 2/1.5 | 0 | 0 | 0/0.0 | 1/6.25 | |||
|
| <0.001 | <0.001 | 0.037 | ||||||
| Yes | 80/61.5 | 20/14.8 | 34/60.7 | 11/19.0 | 13/76.5 | 6/37.5 | |||
| No | 50/38.5 | 115/85.2 | 22/39.3 | 47/81.0 | 4/23.5 | 10/62.5 | |||
|
| <0.001 | <0.001 | 0.001 | ||||||
| Positive | 29/22.3 | 17/12.6 | 11/19.6 | 10/17.2 | 7/41.2 | 4/25.0 | |||
| Negative | 79/60.8 | 92/68.1 | 32/57.2 | 39/67.3 | 9/52.9 | 12/75.0 | |||
| Suspicious | 22/16.9 | 26/19.3 | 13/23.2 | 9/15.5 | 1/5.9 | 0/0.0 | |||
The data are displayed as n/% except otherwise noted.
Mean ± standard deviation
pTCI+, pathologically positive thyroid capsule invasion; pTCI−, pathologically negative thyroid capsule invasion; TSH, thyroid-stimulating hormone; CT, computed tomography; CT-MTD, CT-reported maximum tumor diameter;TCI, thyroid capsule invasion; LN, lymph node.
Figure 3LASSO algorithm for radiomics features selection. (A) Mean square error path using 10-fold cross validation. (B) LASSO coefficient profiles of the radiomics features.
Univariate analysis of clinicoradiological characteristics in the training cohort.
| Univariate analysis | ||
|---|---|---|
| OR (95%CI) |
| |
|
| 1.04 (0.90-1.20) | 0.592 |
|
| 1.00 (0.99-1.01) | 0.245 |
|
| 1.01 (0.98-1.04) | 0.527 |
|
| 1.01 (0.91-1.13) | 0.807 |
|
| 0.97 (0.87-1.08) | 0.558 |
|
| 1.80 (1.60-2.02) | <0.001 |
|
| 1.02 (0.94-1.10) | 0.601 |
TSH, thyroid-stimulating hormone; CT, computed tomography; CT-MTD, CT-maximum tumor diameter; TCI, thyroid capsule invasion; LN, lymph node; OR, odds ratio; CI, confidence interval.
Figure 4ROC curves for the radiomics models in the training (A) and internal test (B) cohorts; ROC curves for the combined models in the training (C) and internal test (D) cohorts.
Figure 5ROC curves of the radiomics models, clinical models and combined models constructed by L-SVM in the training (A), internal test (B) and external test (C) cohorts.
Figure 6ROC curves of PTCs close to thyroid capsule in the internal test (A) and external test (B) cohorts. ROC curves for predicting lesions close to different adjacent structures using the combined L-SVM model in the internal test (C) and external test (D) cohorts. Calibration curves of the combined-L-SVM models in the training, internal test and external test cohorts (E). DCA of the combined-L-SVM models in the training, internal test and external test cohorts (F).